First Manhattan
LOGC

First Manhattan’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

First Manhattan’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed – – 1589
2020
Q4 		$0 Hold
100
– – ﹤0.01% 1441
2020
Q3 		$0 Hold
100
– – ﹤0.01% 1500
2020
Q2 		$0 Hold
100
– – ﹤0.01% 1505
2020
Q1 		$0 Buy
+100
New +$778 ﹤0.01% 1490

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

First Manhattan's LOGC Position: Q1 2021 in Review

First Manhattan sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2021, closing a stake of 100 shares.

First Manhattan first reported a position in LOGC in Q1 2020 and held it in 4 quarters. The position peaked at $0 in Q4 2020. 61 funds tracked by Wall St. Rank hold LOGC as of Q1 2021.

  • First Manhattan reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • First Manhattan sold 100 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2021.
  • First Manhattan first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • First Manhattan's LogicBio Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2020.
  • 61 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2021.

Based on First Manhattan's 13F filing for Q1 2021, filed 14 May 2021.